Carasent is targeting average annual organic revenue growth above 15% during 2024 to 2026. The Company also targets improved profitability, with reported EBITDA margin reaching 25% by 2026 and a reported EBITDAC (EBITDA – capex) margin to reach 15% by 2026. The financial targets are intended for a long-term perspective, and there will be variations between quarters.

“Carasent is entering an exciting new phase building upon our leading market positions and unique offering. We are currently investing heavily into product development that will drive long-term revenue growth. We aim to grow our revenues considerably faster than our costs during the next few years, leading to increasing margins.” says Daniel Öhman, CEO of Carasent.

Long-term financial targets

• Average annual organic revenue growth above 15% during 2024-2026
• EBITDA margin to reach 25% by 2026
• EBITDAC margin to reach 15% by 2026
• We are executing our strategy to reach targets with our current company structure. Potential acquisitions are not included

The CMD will provide investors and analysts with an in-depth overview of Carasent’s structure today, as well as its growth journey, including potential for acquisitions and route for international expansion. The CMD will also provide insights into the Company’s strategy and how it plans to achieve its financial targets.

The CMD will be held at Carnegie Head office in Stockholm at 14:00. A live webcast of the event will also be available on the company’s website. The event will also include a Q&A session with management.

Link for webcast: https://ir.financialhearings.com/carasent-cmd-2023

For further details please contact:

Daniel Öhman, CEO Tel: +46 70-855 37 07, or
Svein Martin Bjørnstad, CFO Tel: +47 979 69 493